ESTRO 2020 Abstract Book

S566 ESTRO 2020

Centre "Mother Teresa"- Tirana- Albania, Statiscics, Tirana, Albania ; 3 University Hospital Centre "Mother Teresa"- Tirana- Albania, Radiology, Tirana, Albania Purpose or Objective To evaluate the efficacy and toxicity of adjuvant CRT in patients after complete resection for gastric cancer. Material and Methods Data of 42 patients with non-metastatic gastric cancer who underwent postoperative CRT with 3D conformal technique during June 2016- January 2018, were analysed. The main endpoints of the study were the evaluation of acute toxicity, local control (LC), disease- free survival (DFS) and overall survival (OS). The rates of acute toxicity were evaluated according to the Common Terminology Criteria for Adverse Events version 4.0. 4.0. The statistical analysis was made through SPSS version 20.0 (SPSS, Chicago, IL). Results The mean age was 59,1± 8.8 years (range 38-76 years). Male to female rate was 4.25:1. Subtotal resection of the stomach was performed in 71.4% of the patients and total gastrectomy in 28.6%. Only one patients didn’t conclude the treatment because of progress disease under treatment. No death occurred due to the therapy. According to histopathology stage, 9.5% were stage IIA, 11.9% stage IIB, 66.2% stage IIIA and 12.1% stage IIIB gastric cancer. Six patients (14.3%) were R1 resection. D1 dissection was performed in 20 patients (47.6%), D2 in 9 (21.4%) and no adequate lymph nodes dissection in 13 patients (30.9%). The radiotherapy doses were 45-50.4 Gy in concomitance with capecitabine in 85.8 %, 5FU/leucoverine in 7,2% and Xelox in 7.2% of the patients. The median follow-up time was 22 months. Distant progression was noted in 10 patients (23.8%), in field progression in 3 patients (7%), in field and distant progression in 2 patients (4%) and stable disease in 27 patients (64.3%). On the close-out date 89.1% patients were still alive, DFS was 64.3% and LC was 88%. D2- lymph nodes dissection was significantly related to better OS (p=0.047) and DFS (p= 0.001). According the toxicity profile, the rate of G3 acute toxicity was 3%.Haematological toxicity observed was G2 neutropenia and G2 anaemia, in 23.8 % and 21% of the patients, respectively. Most common gastrointestinal toxicity was G2 and G3 diarrhea observed in 24% and 14 % respectively and G3 anorexia in 17 % of the patients. Weight loss during radiotherapy, as an indicator of treatment toxicity, was observed in 11 patients (26,2%). No G4 events occurred. Conclusion Our data showed that adjuvant CRT was well tolerated, can safely be administered to patients with gastric cancer, with a low-profile toxicity and favourable survival outcomes. Further study should be conducted to identify prognostic factors that determine the benefit from adjuvant CRT and a longer follow up to evaluate the survival outcome. PO-1066 Clinical results of stereotactic body radiotherapy for elderly hepatocellular carcinoma patients J.Y. Jang 1 , J. Jung 1 , J. Park 1 , J.H. Kim 1 , S.M. Yoon 1 1 Asan Medical Center, University of Ulsan College of Medicine, Department of Radiation Oncology Purpose or Objective The purpose of this study was to investigate the efficacy and safety of stereotactic body radiation therapy (SBRT) for elderly (≥ 75 years) patients with hepatocellular carcinoma (HCC). Material and Methods Between January 2012 and December 2017, 62 patients with HCC who underwent SBRT were reviewed retrospectively. A total dose of 36 – 60 Gy (median, 45)

was delivered with the fraction size of 12 – 15 Gy (median, 15) over 3 – 4 consecutive days. Radiologic response was assessed according to the modified Response Evaluation Criteria in Solid Tumors. Adverse events were graded according to the Common Terminology Criteria for Adverse Events (CTCAE; version 5.0). Radiation-induced liver disease (RILD) was graded according to CTCAE or elevation in the Child-Pugh score to ≥2 in the absence of progressive disease within 3 months after SBRT. Results Patients were 75 to 90 years of age, and 36 (58.1%) were male. Most (93.5%) patients had an Eastern Cooperative Oncology Group performance status of 0 or 1. Fifty-four (88.7%) patients had Child-Pugh class A hepatic function before SBRT. The median tumor size was 2.0 cm (range, 1.0 – 5.9). The median follow-up period of all patients was 27.3 months (range, 7.6 – 86.4) The objective response for each lesion at 3 months after SBRT was 77.3%. The 5-year local tumor control rate was 91.4%. The 3- and 5-year overall survival rates were 59.9% and 33.7%, respectively. Grade ≥3 acute toxicities were observed in 3 (4.8%) patients; however, no patients experienced elevation in the Child-Pugh score to ≥2 after SBRT. Grade ≥3 late toxicity (pleural effusion) was observed in one (1.6%) patient. Conclusion SBRT showed an excellent local tumor control with acceptable toxicities for elderly patients with HCC. SBRT can be a good treatment option in elderly patients with HCC that is unsuitable for curative treatment. PO-1067 Outcomes of combined modality treatment in resectable esophageal carcinoma patients S. Batham 1 , R. Yadav 2 , J.M. Kothari 3 , K. Jani 1 , P. Roy 2 , M. Gandhi 1 , P. Hirapara 4 , D. Parikh 3 , A. Kaushal 5 , V. Lavingia 5 1 HCG Cancer Centre, Radiation Oncology, AHMEDABAD, India ; 2 Sanjay Gandhi Post Graduate Institute of Medical Sciences, Radiation Oncology, Lucknow, India ; 3 HCG Cancer Centre, Surgical Oncology, Ahmedabad, India ; 4 HCG Cancer Centre, Radiation Oncology, Bhavnagar, India ; 5 HCG Cancer Centre, Medical Oncology, Ahmedabad, India Purpose or Objective To evaluate the outcomes of combined modality treatment neo-adjuvant chemo-radiotherapy (CRT) and surgery in resectable esophageal carcinoma patients treated at a tertiary cancer care centre. Material and Methods We audited patients of resectable esophageal carcinoma treated between 2012-2016. Neo-adjuvant CRT comprised of external beam radiotherapy (EBRT) 41.4Gy-50.4Gy in 23-28 fractions along with concurrent weekly Paclitaxel, Carboplatin or weekly Cisplatin. Patient would undergo surgery after a joint clinic discussion based on response and resectability. Results Overall 106 patients were analyzed, with 67(63%) dead, 17(18% lost to follow up (LFU) with or without disease) and 21(20%) alive at a median follow up of 62 months (44 - 82) of those alive. 105 (99%) patients had disease located in mid or lower third, with a median length of 6 cm (2- 15). Among patients who underwent surgery (68 patients), 21 (29.4%) were pathological complete responders (pCR) while 7 (10%) patients intra-op were found to have unresectable or metastatic disease and did not undergo resection. Median and 2 and 5-year OS were 23months, 48% and 31% (best case scenario, LFU-censored) vs. 18months, 43% and 22% (worst case scenario, LFU-events). Median and 2-yr OS of patients (worst case scenario), who did or did not undergo surgery was (19 versus 15 months), (49% versus 32%) which was not statistically significant (p= 0.10). Among those who were operated, patients achieving pCR fared better than those who did not, median OS (38